Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and ...
Women are more likely to have pulmonary arterial hypertension, but men tend to have worse outcomes and worse treatment responses.
Advanced therapies, medicines bring new hope for pulmonary hypertension patients: Dr Manisha Mendiratta: Shardul Nautiyal, Mumbai Saturday, February 8, 2025, 08:00 Hrs [IST] Dr Ma ...
Seropositive rheumatoid arthritis may be protective against the development of PAH, based on results of Mendelian randomization analyses.
Eko Health, a leader in applying artificial intelligence (AI) for the early detection of heart and lung diseases, today ...
The HYPERION study was evaluating Winrevair in recently diagnosed adults with pulmonary arterial hypertension.
Combination therapy with oral or inhaled treprostinil may benefit patients with pulmonary arterial hypertension and cardiovascular comorbidities.
Rahway: Merck, known as MSD outside of the United States and Canada, has announced the Phase 3 HYPERION study evaluating ...
TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with ...
The phase 3 HYPERION trial of Winrevair in adults with newly diagnosed pulmonary arterial hypertension functional class two ...
DelveInsight's Pulmonary Arterial Hypertension Market report offers an in-depth understanding of the epidemiology and market trends in the 7MM. LAS VEGAS, NV, UNITED STATES, January 9, 2025 ...
F-FAPI PET -- can detect the first signs of tissue remodeling in patients with pulmonary arterial hypertension (PAH), providing physicians with an early marker for disease progression. This approach ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback